Emmaus Life Sciences, Inc. (OTCMKTS:EMMA) Short Interest Down 51.5% in February

Emmaus Life Sciences, Inc. (OTCMKTS:EMMA) saw a significant decline in short interest in the month of February. As of February 28th, there was short interest totalling 4,900 shares, a decline of 51.5% from the February 13th total of 10,100 shares. Based on an average trading volume of 145,500 shares, the days-to-cover ratio is currently 0.0 days. Approximately 0.0% of the shares of the company are short sold.

Emmaus Life Sciences Stock Down 2.1 %

Shares of EMMA stock traded down $0.00 during trading hours on Friday, hitting $0.03. 20,578 shares of the company’s stock were exchanged, compared to its average volume of 53,421. The firm has a market cap of $1.75 million, a P/E ratio of -0.30 and a beta of 6.47. The firm has a 50 day moving average of $0.02 and a two-hundred day moving average of $0.02. Emmaus Life Sciences has a fifty-two week low of $0.00 and a fifty-two week high of $0.13.

About Emmaus Life Sciences

Emmaus Life Sciences, Inc, a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older.